论文部分内容阅读
据《自然》周刊报道,曾经被认为可能奇迹般治愈癌症的干扰素现已作为日本生物技术产业的一个重要组成部分而迅速兴起:它可用于治疗目前在日本流行的一种病毒性肝炎。自从干扰素被厚生省批准可用于治疗慢性肝炎C以来,其销售量已从1991年的300亿日元(约2.5亿美元)猛增到去年的1500亿日元。据《日经生物技术》预测,今年干扰素在日本的销售量可望超过2000亿日元,大约相当于日本整个生物技术市场的1/3。事实上,它的加速增长已导致大藏省提出应限
According to the weekly Nature, interferon, once thought to miraculously cure cancer, has now emerged as an important part of the biotech industry in Japan: It can be used to treat a type of viral hepatitis currently circulating in Japan. Since interferon was approved by the Ministry of Health for treatment of chronic hepatitis C, its sales have soared from 30 billion yen (about 250 million U.S. dollars) in 1991 to 150 billion yen last year. According to “Nikkei Biotechnology” forecast, this year's sales of interferon in Japan is expected to exceed 200 billion yen, equivalent to about 1/3 of Japan's entire biotechnology market. In fact, its accelerated growth has led the Ministry of Finance to propose that it should be limited